Repligen (NASDAQ:RGEN) Reaches New 1-Year High – Still a Buy?

Repligen Corporation (NASDAQ:RGEN)’s share price reached a new 52-week high on Wednesday . The company traded as high as $179.87 and last traded at $177.8660, with a volume of 224928 shares traded. The stock had previously closed at $166.15.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Barclays upped their price objective on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $166.43.

Repligen Stock Performance

The business’s 50-day moving average price is $146.14 and its 200-day moving average price is $131.54. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a market cap of $10.18 billion, a PE ratio of 246.97, a P/E/G ratio of 3.22 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the company earned $0.26 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Institutional Trading of Repligen

Several large investors have recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the third quarter worth $29,000. Bayforest Capital Ltd acquired a new stake in Repligen during the fourth quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC purchased a new position in Repligen in the fourth quarter valued at $36,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen in the 2nd quarter valued at about $52,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.